Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JGA Vows Strict Response to Choseido’s Biz Suspension Order
The Japan Generic Medicines Association (JGA) said on October 11 that it will take a strict response to a business suspension order issued the same day to its member company Choseido Pharmaceutical over its manufacturing issues. “This severe administrative penalty…
To read the full story
Related Article
- Choseido’s Kawauchi Plant Suspended for 1 Month on GMP Violation
March 28, 2025
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
ORGANIZATION
- CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
- PhRMA Welcomes Honebuto, Prods Japan to Launch Reform This Year
July 22, 2026
- JPMA Backs Honebuto 2026 Innovation Agenda
July 21, 2026
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…